Distinct Functional Metagenomic Markers Predict the Responsiveness to Anti-PD-1 Therapy in Chinese Non-Small Cell Lung Cancer Patients

BACKGROUND: Programmed death 1 (PD-1) and the ligand of PD-1 (PD-L1) are central targets for immune-checkpoint therapy (ICT) blocking immune evasion-related pathways elicited by tumor cells. A number of PD-1 inhibitors have been developed, but the efficacy of these inhibitors varies considerably and...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Chao, Fang, Wenfeng, Xu, Liqin, Gao, Fangfang, Hou, Yong, Zou, Hua, Ma, Yuxiang, Moll, Janne Marie, Yang, Yunpeng, Wang, Dan, Huang, Yan, Ren, Huahui, Zhao, Hongyun, Qin, Shishang, Zhong, Huanzi, Li, Junhua, Liu, Sheng, Yang, Huanming, Wang, Jian, Brix, Susanne, Kristiansen, Karsten, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069064/
https://www.ncbi.nlm.nih.gov/pubmed/35530307
http://dx.doi.org/10.3389/fonc.2022.837525

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069064/
https://www.ncbi.nlm.nih.gov/pubmed/35530307
http://dx.doi.org/10.3389/fonc.2022.837525

Ejemplares similares